Company news

NeuroSense Therapeutics Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data

November 2, 2026

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

October 29, 2026

NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

October 19, 2026

NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones

October 13, 2026

NeuroSense Provides Update on Nasdaq Listing Compliance

October 2, 2026

NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

September 28, 2026

NeuroSense Provides Business Update and Progress for the First Half of 2026

September 25, 2026

NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference

September 10, 2026

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

August 31, 2026

NeuroSense Issues CEO Letter to Shareholders

August 13, 2026

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

August 6, 2026

NeuroSense Advances PrimeC toward New Drug Submission to Health Canada for ALS

July 23, 2026

NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

July 22, 2026

NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"

July 6, 2026

NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS

June 29, 2026

NeuroSense Therapeutics Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

June 25, 2026

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

June 25, 2026

EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots

June 22, 2026

NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS

June 11, 2026

NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition

June 8, 2026

NeuroSense Announces Pricing of Insider-Led PIPE Financing

April 27, 2026

NeuroSense Granted Brazilian Patent Covering PrimeC Composition

April 6, 2026

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

April 2, 2026

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

March 31, 2026

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

March 23, 2026

Correction: NeuroSense

March 17, 2026

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

March 15, 2026

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

March 8, 2026

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

February 18, 2026

NeuroSense Expands Global IP Protection Strategy with Granted Australian Patent Covering PrimeC Composition

February 10, 2026

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

February 9, 2026

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

January 21, 2026

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

January 8, 2026

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

December 22, 2025

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

December 4, 2025

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

November 24, 2025

NeuroSense to Host Investor Webinar on December 8, 2025

November 3, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

October 6, 2025

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

September 10, 2025

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

September 4, 2025

NeuroSense Provides Business Update and Progress for the First Half of 2025

July 30, 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

July 22, 2025

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

April 24, 2025

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

April 9, 2025

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

April 7, 2025

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

April 4, 2025

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

March 20, 2025

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

January 5, 2025

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

December 22, 2024

Older news releases →

Decks

The 5 newest of 18 decks. Every deck is listed under its year.